Two drugs shown to prolong survival in advanced melanoma cases
Two new drugs prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure.
The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration. The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March.
Research on both drugs was presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago while also being published simultaneously online in the New England Journal of Medicine.























